Esperion Therapeutics, Inc.
ESPRDelisted Jul 13, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434868
Esperion Therapeutics, Inc. was delisted on Jul 13, 2026; its insiders filed their last Form 4 on Jul 13, 2026; 191 institutions reported holding it in 13F filings for Q2 2026, worth $646.8M in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q4 2024
Institutional positions in Esperion Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 190
- +8 vs. Q3 2024
- Shares held
- 126.3M
- +619.0K (+0.5%) vs. Q3 2024
- Total value
- $277.9M
- +$69.9M (+33.6%) vs. Q3 2024
- New holders
- 34
- 55 more added
- Sold out
- 26
- 44 more reduced
2 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ESPR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 191 | $646.8M |
| Q1 2026 | 207 | $479.3M |
| Q4 2025 | 201 | $559.6M |
| Q3 2025 | 189 | $286.1M |
| Q2 2025 | 164 | $96.6M |
| Q1 2025 | 187 | $171.5M |
| Q4 2024 | 190 | $277.9M |
| Q3 2024 | 184 | $214.3M |
| Q2 2024 | 176 | $304.2M |
| Q1 2024 | 152 | $336.2M |
| Q4 2023 | 132 | $215.3M |
| Q3 2023 | 123 | $75.9M |
| Q2 2023 | 124 | $103.6M |
| Q1 2023 | 165 | $129.1M |
| Q4 2022 | 164 | $457.6M |
| Q3 2022 | 148 | $425.5M |
| Q2 2022 | 137 | $352.1M |
| Q1 2022 | 132 | $241.2M |
| Q4 2021 | 133 | $268.0M |
| Q3 2021 | 139 | $299.4M |
| Q2 2021 | 142 | $599.4M |
| Q1 2021 | 156 | $805.3M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Esperion Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Whitebox Advisors LLC | 0 | $0 | 0.00% | −30,182−100.0% | Sold out |
| Versor Investments LP | 0 | $0 | 0.00% | −26,400−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | −25,692−100.0% | Sold out |
| Wealth Enhancement Advisory Services, LLC | 0 | $0 | 0.00% | −23,661−100.0% | Sold out |
| Traphagen Investment Advisors LLC | 0 | $0 | 0.00% | −16,200−100.0% | Sold out |
| Pekin Hardy Strauss, Inc. | 0 | $0 | 0.00% | −14,500−100.0% | Sold out |
| LPL Financial LLC | 0 | $0 | 0.00% | −13,548−100.0% | Sold out |
| Wolverine Trading, LLC | 0 | $0 | 0.00% | −10,969−100.0% | Sold out |
| Meridian Wealth Management, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Texas Capital Bank Wealth Management Services Inc | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −3,030−100.0% | Sold out |
| Global Retirement Partners, LLC | 0 | $0 | 0.00% | −2,448−100.0% | Sold out |
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −770−100.0% | Sold out |
| South State Corp. | 0 | $0 | 0.00% | −314−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −193−100.0% | Sold out |
| Brown, Lisle/Cummings, Inc. | 0 | $0 | 0.00% | −190−100.0% | Sold out |
| Meditor Group Ltd | – | – | – | – | Not filed |
| Raymond James & Associates | – | – | – | – | Not filed |